**Title Page**

**Title: Mucin-7 as a Potential Candidate Risk Allele for Cleft Lip and/or Palate**

**Authors:** Rachel A. Montel, Ph.D., Tatiana P. Rengifo, B.S., and Sulie L. Chang, Ph.D.

**Affiliations:** Department of Biological Sciences, Seton Hall University, South Orange, NJ 07079 (Montel, Rengifo, Chang); Institute for Neuroimmune Pharmacology, Seton Hall University, South Orange, NJ 07079 (Rengifo, Chang)

## Abstract

Cleft lip and/or palate (CL/P) occur in approximately 1 in 700 live births in the United States. High hereditary rates (50-80%) of CL/P indicate a strong genetic cause. The concept of strong genetic causes has been well-demonstrated in previous studies such as GWAS studies that identified *IRF6* for Van der Woode syndrome. Since the risk for genetic factors is strongly associated with CL/P, we hypothesized that RNA sequencing (RNA-seq) from CL/P patients may reveal enriched genes. Differential expression analysis examined changes in gene expression in CL/P patients compared to healthy controls, and gene-enrichment in relevant pathways. To explore the relationship between variants driving the observed changes in gene expression, we performed variant analysis and reported all CL/P-specific single nucleotide polymorphisms (SNPs). Our findings demonstrate that the normally upregulated *MUC7* gene is significantly downregulated in CL/P patients. Using our list of prioritized differentially expressed genes (DEGs), we observed significantly enriched pathways for biological processes related to cornification, skin and epidermis development, and keratinocyte and epidermal cell differentiation. By performing variant analyses, a single nucleotide polymorphism (SNP) in *MUC7*, and 47 SNPs in 20 additional genes (*CLCA4*, *ETNK2*, *ERLNC1*, *HAL*, *HOPX*, *IVL*, *KLK11*, *LIPK*, *LY6D*, *MUC21*, *NCCRP1*, *NEBL*, *PHYH*, *SERPINB11*, *SERPINB4*, *SORD*, *SPINK5*, *SULT2B1*, *TMEM154*, *TMPRSS11A*) were revealed. To our knowledge, this is the first

report on the potential role of *MUC7* in contributing to CL/P. Together, these findings provide further insight into the genetic causes of CL/P.

## Introduction

Clefts of the lip and/or palate (CL/P), congenital orofacial malformations, are common birth defects of the lip and/or palate, affecting 1 in 700 live births worldwide and 16.86 per 10,000 live births in the United States[1,2]. CL/P is divided into three categories: cleft lip with palate (CLP), isolated cleft lip (CL), and isolated cleft palate (CP) with CLP occurring at the highest prevalence with the worst outcomes[3]. The consequence of this complex anomaly has lifelong implications for affected individuals and requires multidisciplinary treatment[4-6].

The etiology of CL/P is multifactorial. Genetic and environmental factors play a role with an estimated heritability rate between 50 and 80%[7-9]. CL/P research in the past few years has been marked by significant breakthroughs with studies characterizing the underlying gene defects associated with several important clefting syndromes[10-15]. Interferon regulatory factor-6 (*IRF6*) gene was shown to cause van der Woude syndrome and the poliovirus receptor related-1 (*PVRL1*) gene is responsible for an autosomal recessive ectodermal dysplasia syndrome associated with clefting[16-20]. With the use of newer technologies, genome-wide association studies (GWAS) in CL/P explained about 60 common risk loci[21]. Still, the genetic basis of CL/P remains unclear and demonstrates a significant gap in knowledge.

Given this information, we hypothesized that using the RNA sequencing (RNA-seq) data from CL/P patients could reveal the role of high impact genes that could increase the risk of CL/P[23-24]. To assess this hypothesis, we examined (1) gene expression in CL/P patients compared to healthy controls, (2) gene-enrichment in relevant pathways, and (3) single nucleotide polymorphisms (SNPs) potentially driving upregulation or downregulation in expression. Our study comprehensively examined compensations in gene expression in CL/P-related pathways. The purpose of this paper is the opportunity to use bioinformatics to explore differential changes in gene expression and SNPs contributing to the etiology of CL/P.

## Methods

### Information on sequencing data

All RNA-seq data used in this study was accessed from NCBI (SRR13662566). SRA were selected for samples related to CL/P and six patient sample SRAs were downloaded as uploaded by Zhang et al[22]. This set contains whole blood samples from 4 CL/P patients and 2 healthy controls.

### Differential expression analysis

Differential expression analyses were performed using the Advanced RNA-seq workflow in CLC Genomics Workbench[25] and the human hG38 reference genome as map. The RNA-seq workflow was used to align the sequences of each sample against the predicted gene and transcript tracks, using the human hG38 reference genome as map. Transcript levels were quantified in reads per kilobase per mapped reads (RPKM). False discovery rate (FDR) p-values and absolute fold change for the differentially expressed genes (DEGs) were calculated. The p-values were log-transformed. Significant DEGs were visualized using the VolcaNoseR volcano plot[26].

### Functional enrichment analysis

Canonical pathway enrichment was performed using Ingenuity Pathway Analysis (IPA) suite (version 1.0, Qiagen, German)[27]. Enrichment pathways of the DEGs were generated based on the IPA database. Significantly enriched DEGs were identified as members of pathways and functional categories using Fisher's exact test. All relevant gene regulatory networks were observed in Ingenuity Knowledge Base.

Gene ontology was analyzed using PANTHER Classification System[28]. Several pathways were selected for their role in biological processes that are or may be related to CL/P. Ancestor charts were generated with AmiGO2[29,30]. Gene annotation was based on 1000 Genomes[31] [internationalgenome.org], GTEx portal[32] [www.gtexportal.org], GenAtlas[33] [bio.tools/genatlas], and GnomAD[34] [http://gnomad.broadinstitute.org].

**SNP variant detection**

Single-variant analysis was performed using the Basic Variant Detection workflow in CLC Genomics Workbench. Enriched variants common in CL/P compared to healthy controls were identified using the Fisher exact test. All variants in protein-coding regions in CL/P samples were selected; 5'UTR and intronic variants were excluded. Variants were sorted by gene and prediction scores (Polyphen and SIFT)[35] were reported.

**Results**

In the context that CL/P has evidence of genetic susceptibility, we hypothesized gene expression may be upregulated or downregulated in CL/P individuals compared to healthy controls. Using RNA sequencing, significant changes in gene expression were observed. To further test the status of differentiation-related genes and the quantitation of gene expression, statistical analyses were performed. Compared to healthy controls, CL/P individuals showed significant upregulation for *MAL2* ($p<10^{-35}$) and downregulation for *MUC7* ($p<10^{-113}$) as assessed by differential expression analysis (Figure 1).

We prioritized a set of genes (FDR p-value$<10^{-28}$) out of 2961 differentially expressed genes (FDR p-value<0.05). Among our list of prioritized genes, the genes known to play a significant role in the development of the palate are *MUC7*, *DMBT1*, *MUC19*, *ZG16B*, *MUC5B*,

*BPIFB2*, *TCN1*, *PIGR*, *MAL2*, and *SCGB3A1*. The genes contributing to development, cell regulation, or cell differentiation are *DMBT1* and *SCGB3A1*. In the family of mucin genes normally upregulated in the minor salivary glands, *MUC7*, *MUC19*, and *MUC5B* are enriched. Since the mucin genes are found in the minor salivary glands, this gene family is of high importance for CL/P. We observed two normally upregulated genes *MUC7* ($p<10^{-113}$) and *MUC19* ($p<10^{-72}$) were significant downregulated (Figure 1). Consistent with our interest in this gene family, we analyzed the *MUC7* pathway using IPA for overlapping between *MUC7* and other relevant genes (Figure 2). One interaction important to our findings was observed for *MUC7* and *SERPINB4*.

Based on the concept that cleft lip and palate occurs in response to disruptions during embryogenesis and/or development, we investigated the top disease and biological functions. For the category of diseases and disorders, cancer, organismal injury and abnormalities, endocrine system disorders, gastrointestinal disease, and dermatological diseases and conditions were significantly enriched (Table 1). For the category of physiological system development and function, embryonic development, hair and skin development and function, organ development, organismal development, and tissue development were significantly enriched (Table 2). In looking at biological processes related to our differential expression set, cornification, skin development, keratinocyte differentiation, epidermis development, and epidermal cell differentiation were significantly enriched (Figure 3a). When we expanded our analysis to include molecular function, proton-transporting ATP synthase activity was significantly enriched along with other transporter activities (Figure 3b). Since cornification embodies pathways related to development and differentiation of the skin, keratin and epidermis, the cornification pathway was further explored (Figure 4). Our observations of the pathway for cornification demonstrate

an important role in processes such as keratinization, epidermal cell differentiation, skin development and tissue development, that are strongly related to CL/P.

Since changes in gene expression may be from gene variations, we investigated if any single nucleotide polymorphisms (SNPs) were associated with the status of differentiation-related genes. To assess SNPs present in CL/P individuals but absent in healthy controls, variant analysis using CLC Workbench was performed. We selected all SNPs in protein-coding regions observed only in CL/P samples and prediction scores (Polyphen, SIFT)[35] were reported. Forty-eight SNPs were observed across 21 genes (*CLCA4*, *ETNK2*, *ERLNC1*, *HAL*, *HOPX*, *IVL*, *KLK11*, *LIPK*, *LY6D*, *MUC21*, *MUC7*, *NCCRP1*, *NEBL*, *PHYH*, *SERPINB11*, *SORD*, *SPINK5*, *SULT2B1*, *TMEM154*, *TMPRSS11A*) (Table 2). Of the observed SNPs, 4 were predicted as possibly damaging, 6 were predicted as probably damaging, and 15 were predicted as unknown. Out of the 21 genes, SNPs were observed in *MUC7* (rs145745951) and *SERPINB4* (rs576273012); these genes were shown to interact in IPA's *MUC7* pathway analysis (Figure 2).

**Discussion**

Recent studies demonstrate that syndromes of CL/P have strong genetic links and CL/P hereditability is between 50% and 80%[7-9]. Based on these observations, we hypothesized that cleft lip and palate may have altered transcriptomic expression in RNA sequencing from CL/P patients. Our findings demonstrate that the normally upregulated *MUC7* found in the minor salivary gland is downregulated in CL/P patients. *MUC7* encodes mucin-7, a small salivary mucin found the minor salivary glands. To our knowledge, this is the first report on the association of *MUC7* with CL/P. We also observe another normally upregulated family of the mucin genes, *MUC19*, is similarly downregulated.

It is well understood that CL/P forms from disruptions during embryonic developmental processes including those of respiration, facial and dental development, and many of the syndromic genes associated with CL/P are expressed in a variety of tissues and organs[1-3]. As part of this study to assess gene-set enrichment, our analysis identified 1) significantly enriched genes whose gene expression may contribute to the risk of CL/P and 2) significant enrichment in pathways for physiological system development and function, and diseases and disorders involved in CL/P. We observed pathways related to embryonic development, hair and skin development and function, organ development, organismal development, and tissue development were enriched. These enriched pathways support the concept that explanations for risk for CL/P could lie in genes related to these pathways. Since the enriched pathways provided evidence for CL/P, we explored biological process enrichment and observed cornification was significantly enriched (fold enrichment 4). Cornification is the process in which epidermal keratinocytes undergo terminal differentiation and programmed cell death; that results in the formation of the outermost skin barrier.

Based on the concept that changes in gene expression often results from variations in SNPs, we hypothesized that SNPs would be found in the most significantly upregulated or downregulated genes. Our findings demonstrate that 10 out of 48 SNPs were potentially damaging. Based on our observations that *MUC7* is differentially expressed, a single SNP (rs145745951) was reported. The prediction of this SNP using Polyphen was 'unknown' indicating that further studies should be performed to characterize the influence of this SNP on mucin-7 functionality. We also observed a SNP (rs576273012) in *SERPINB4* found in the *MUC7* pathway generated in IPA.

Together, our study suggests that *MUC7* may contribute to clefting in CL/P individuals. The evidence that *MUC7* is differentially downregulated with a single SNP present can

encourage a mechanistic study to confirm our observations. Although this study presents strong evidence for the role of *MUC7* in CL/P, alternative and additional genes and regulatory elements could provide other possible mechanisms of clefting. This evidence promotes the concept that clefting and the development of CL/P have a strong genetic influence.

**Literature Citations**


1. Dixon, M.J. et al. Cleft lip and palate: understanding genetic and environmental influences. *Nature Reviews Genetics*. **12**, 167-178 (2011).
2. Canfield, M.A. et al. National estimates and race/ethnic-specific variation of selected birth defects in the United States. *Bir. Defects. Res A Clin Mol. Teratol*. **76**, 747-756 (2006).
3. Cobourne, Martyn T. The complex genetics of cleft lip and palate. *European journal of orthodontics*. **26**, 7-16 (2004).
4. Chuo, C.B. et al. The Continuing Multidisciplinary Needs of Adult Patients with Cleft Lip and/or Palate. *The Cleft Palate Craniofacial Journal*. **45**, 633-638 (2008).
5. Habel, A., Sell, D., & Mars, M. Management of cleft lip and palate. *Archives of Disease in Childhood*. **74**, 360-366 (1996).
6. Wehby G. & Cassell, C.H. The impact of orofacial clefts on quality of life and healthcare use and costs. *Oral Dis.* **16**, 3-10 (2010).
7. Murray, J.C. Gene/environment causes of cleft lip and/or palate. *Clin. Genet.* **61**, 248-256 (2002).
8. Little, J., Cardy, A., & Munger, R.G. Tobacco smoking and oral clefts: a meta-analysis. *Bull World Health Organ*. **82**, 213-218 (2002).
9. Grosen, D. et al. Risk of oral clefts in twins. *Epidemiology*. **22**, 313-319 (2011).
10. Marazita, M.L. et al. Genome scan, fine-mapping, and candidate gene analysis of non-syndromic cleft lip with or without cleft palate reveals phenotype specific differences in linkage and association results. *Hum. Hered*. **68**, 151-170 (2009).
11. Birnbaum, S. et al. Key susceptibility locus for nonsyndromic cleft lip with or without cleft palate on chromosome 8q24. *Nature Genet.* **41**, 473–477 (2009).

12. Grant, S. F. et al. A genome-wide association study identifies a locus for nonsyndromic cleft lip with or without cleft palate on 8q24. *J. Pediatr.* **155**, 909–913 (2009).

13. Mangold, E. et al. Genome-wide association study identifies two susceptibility loci for nonsyndromic cleft lip with or without cleft palate. *Nature Genet.* **42**, 24–26 (2010).

14. Beaty, T. H. et al. A genome-wide association study of cleft lip with and without cleft palate identifies risk variants near MAFB and ABCA4. *Nature Genet.* **42**, 525–529 (2010).

15. Avasthi, K.K. et al. Identification of Novel Genomic Variations in Susceptibility to Nonsyndromic Cleft Lip and Palate Patients. *Pediatric reports* **13**, 650-657 (2021).

16. Kondo, S. et al. Mutations in *IRF6* cause Van der Woude and popliteal pterygium syndromes. *Nature Genet.* **32**, 285–289 (2002).

17. Huaxiang, Z. et al. A novel IRF6 mutation causing non-syndromic cleft lip with or without cleft palate in a pedigree, *Mutagenesis*. **33**, 195–202 (2018).

18. Park, J.W. et al. Association between IRF6 and nonsyndromic cleft lip with or without cleft palate in four populations. *Genet Med.* **9**, 219-227 (2007).

19. Thompson, J. et al. A cleft lip and palate gene, Irf6, is involved in osteoblast differentiation of craniofacial bone. *Dev Dyn*. **248**, 221-232 (2019).

20. Avila, J.R. et al. PVRL1 variants contribute to non-syndromic cleft lip and palate in multiple populations. *Am J Med Genet* A. **140**, 2562-2570 (2006).

21. Awotoye, W. et al. Whole-genome sequencing reveals de-novo mutations associated with nonsyndromic cleft lip/palate. *Sci Rep*. **12**, 11743 (2022).

22. Zhang, B. et al. DNA methylation profile of lip tissue from congenital nonsyndromic cleft lip and palate patients by whole-genome bisulfite sequencing. *Birth defects research*, 1-13 (2022).

23. Shu, X. et al. Identification of circular RNA-associated competing endogenous RNA network in the development of cleft palate. *Journal of cellular biochemistry*. **120**, 16062-16074. (2019).

24. Jia, S. et al. Identification by RNA-seq of let-7 clusters as prenatal biomarkers for nonsyndromic cleft lip with palate. *Ann NY Acad Sci*. **1516**, 234-246 (2022).

25. Liu, C.H., & Di, Y.P. Analysis of RNA Sequencing Data Using CLC Genomics Workbench. In: Keohavong, P., Singh, K., Gao, W. (eds) Molecular Toxicology Protocols. Methods in Molecular Biology, vol 2102. Humana, New York, NY.

26. Goedhart, J., & Luijsterburg, M.S. VolcaNoseR is a web app for creating, exploring, labeling and sharing volcano plots. *Sci Rep* **10**, 20560 (2020).

27. Krämer, A et al. Causal analysis approaches in Ingenuity Pathway Analysis. *Bioinformatics*. **30**, 523-530 (2014).

28. Mi, H. et al. Large-scale gene function analysis with the PANTHER classification system. *Nat Protoc*. **8**, 1551-1566. (2018).

29. Ge, S.X., Jung, D. & Yao, R. ShinyGO: a graphical gene-set enrichment tool for animals and plants. *Bioinformatics* **36**, 2628–2629 (2020).

30. Carbon, S. et al. AmiGO: online access to ontology and annotation data. *Bioinformatics*. **25**, 299-289 (2009).

31. Clarke, L. et al. The 1000 Genomes Project: data management and community access. *Nat Methods*. **9**, 459-462 (2012).

32. Lonsdale, J. et al. The Genotype-Tissue Expression (GTEx) project. *Nat Genet*. **45**, 580-585 (2013).

33. Frézal J. Genatlas database, genes and development defects. *C R Acad Sci III*. **321**, 805-817 (1998).

34. Karczewski, K.J. et al. The mutational constraint spectrum quantified from variation in 141,456 humans. *Nature*. **581**, 434-443 (2020).

35. Flanagan, S.E., Patch, A., & Ellard, S. Using SIFT and PolyPhen to Predict Loss-of-Function and Gain-of-Function Mutations. *Genetic Testing and Molecular Biomakers*. **14**, 533-537 (2010).

**Table 1. Significantly Enriched Pathways for Physiological Systems and Functions**[24]

| Name | p-value range | # Molecules |
|---|---|---|
| Embryonic Development | 3.98E-04 - 1.71E-11 | 187 |
| Hair and Skin Development and Function | 3.74E-04 - 1.71E-11 | 122 |
| Organ Development | 3.98E-04 - 1.71E-11 | 244 |
| Organismal Development | 4.80E-04 - 1.71E-11 | 430 |
| Tissue Development | 4.70E-04 - 1.71E11 | 287 |

**Table 2. Significantly Enriched Pathways for Diseases and Disorders**[24]

| Name | p-value range | # Molecules |
|---|---|---|
| Cancer | 4.71E-04 - 2.46E-139 | 2154 |
| Organismal Injury and Abnormalities | 5.02E-04 - 2.46E-139 | 2183 |
| Endocrine System Disorders | 1.22E-04 - 2.54E-39 | 1667 |
| Gastrointestinal Disease | 4.50E-04 - 3.22E-37 | 1823 |
| Dermatological Diseases and Conditions | 3.85E-04 - 6.58E-33 | 1467 |

## Figure Legends

**Figure 1. *MUC7* is differentially expressed in lip tissues of CL/P patients than healthy controls.** Volcano plot showing DEGs derived from volcanoplot analysis of CL/P patients from healthy controls. Differentially expressed genes are noted (FDR<$10^{-28}$); all upregulated (red) and downregulated (blue) genes are shown. The FDR cut-off was p-value<0.05. P-value was calculated by Fisher's exact test.

**Figure 2. The role of *MUC7* with interacting genes.** The MUC7 pathway was explored in IPA pathway analysis[27] and organized by cellular location. The interaction of MUC7 with SERPINB4 is of particular importance since both genes contain SNPs based on our variant analysis.

**Figure 3. Biological process and molecular function for all differentially expressed genes.** (A) Biological process for all differentially expressed genes. (B) Molecular function for all differentially expressed genes. Enrichment plot produced by ShinyGO (version 0.76.3)[29].

**Figure 4. Cornification ancestor chart for significantly enriched biological processes.** Gene ontology (GO) process for cornification (fold enrichment 4) demonstrating biological and cellular processes involved[30]. The processes involved in cornification include keratinization, epidermal cell differentiation, skin development and tissue development, which are strongly related to CL/P.

Expression Browser-1



MUC7




© 2000-2023 QIAGEN. All rights reserved.


Cornification
Aerobic respiration
Cellular respiration
Energy derivation by oxidation of organic compounds
Skin development
Keratinocyte differentiation
Epidermis development
Epidermal cell differentiation
Neutrophil activation involved in immune response
Neutrophil degranulation
Neutrophil activation
Neutrophil mediated immunity
Granulocyte activation
Generation of precursor metabolites and energy
Small molecule biosynthetic proc.
Exocytosis
Cellular lipid metabolic proc.
Transmembrane transport
Lipid metabolic proc.
Intracellular transport
0
1
2
3
4
Fold Enrichment
N. of Genes
100
150
200
250
-log10(FDR)
10
11
12
13
14


Proton-transporting ATP synthase activity, rotational mechanism
Proton channel activity
Oxidoreductase activity, acting on a heme group of donors
Proton transmembrane transporter activity
Oxidoreduction-driven active transmembrane transporter activity
Electron transfer activity
Structural constituent of ribosome
Active ion transmembrane transporter activity
Actin filament binding
Primary active transmembrane transporter activity
Inorganic cation transmembrane transporter activity
Inorganic molecular entity transmembrane transporter activity
Oxidoreductase activity
Cation transmembrane transporter activity
Ion transmembrane transporter activity
Actin binding
Structural molecule activity
Transmembrane transporter activity
Transporter activity
Cytoskeletal protein binding
0
2
4
6
Fold Enrichment
N. of Genes
50
100
150
200
-log10(FDR)
4
6
8
10




QuickGO - https://www.ebi.ac.uk/QuickGO